Table 3 Multivariable Cox proportional hazards models of uric acid, individual NCCN-IPI items, and serum creatinine for the prediction of overall and PFS in patients with DLBCL (n=539)

From: NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients

 

Multivariable analysis OS

Multivariable analysis PFS

Variable

HR (95% CI)

P -value

HR (95% CI)

P -value

Uric acid (per 1 log increase)

1.54 (1.07–2.22)

0.020

1.45 (1.05–2.01)

0.025

Age category

    

40 years

1 (ref.)

1 (ref.)

 41–60 years

1.97 (0.56–6.88)

0.289

1.43 (0.64–3.18)

0.385

 61–75 years

3.98 (1.24–12.74)

0.020

2.10 (1.01–4.36)

0.048

 >75 years

9.31 (2.90–29.95)

<0.0001

3.64 (1.73–7.68)

0.001

Site

    

 No extranodal disease

1 (ref.)

1 (ref.)

 Extranodal disease

1.21 (0.88–1.65)

0.242

1.16 (0.87–1.54)

0.317

LDH ratio

    

 <ULN

1 (ref.)

1 (ref.)

 1–3 × ULN

1.22 (0.85–1.75)

0.286

1.26 (0.91–1.75)

0.157

 >3 × ULN

1.87 (1.15–3.03)

0.011

1.93 (1.23–3.02)

0.004

Clinical stage (Ann Arbor)

    

 I&II

1 (ref.)

1 (ref.)

 III&IV

1.78 (1.27–2.48)

0.001

1.55 (1.15–2.09)

0.004

ECOG PS

    

 0–2

1 (ref.)

1 (ref.)

2

1.46 (1.00–2.12)

0.049

1.40 (0.98–1.99)

0.065

 Serum creatinine (per 1 mg dl−1 increase)

1.04 (0.89–1.21)

0.643

1.00 (0.85–1.17)

0.951

  1. Abbreviations: CI=confidence interval; DLBCL=diffuse large B-cell lymphoma; ECOG PS=Eastern Cooperative Oncology Group (ECOG) performance status (PS); HR=hazard ratio; LDH=lactate dehydrogenase; NCCN-IPI=National Comprehensive Cancer Network International Prognostic Index; OS=Overall survival; P=Wald-test P-value; PFS=progression-free survival. Bold indicates P<0.05.